AI Article Synopsis

  • Endometrial hyperplasia (EH) can lead to endometrial cancer (EC), with a significant percentage of patients showing EC after hysterectomy, especially when atypical cells are present.
  • In postmenopausal women on anticoagulant therapy (OAT), uterine bleeding may indicate precancerous or cancerous endometrial conditions.
  • The study found that women diagnosed with non-atypical endometrial hyperplasia (NAEH) who were on OAT had nearly five times the risk of having more advanced lesions compared to those not on OAT.

Article Abstract

: Endometrial hyperplasia (EH) is a precursor lesion to endometrial cancer (EC), and when cellular atypia is present, in 40% of cases, they are diagnosed with EC on hysterectomy. Usually, EH is clinically manifested by uterine bleeding. In patients with oral anticoagulant therapy (OAT), the uterus is the second most common source of bleeding. The aim of the study was to show that uterine bleeding in postmenopausal patients undergoing OAT may reveal precancerous endometrial lesions with atypia, or neoplastic lesions in patients with an initial diagnosis of endometrial hyperplasia without atypia (non-atypical endometrial hyperplasia, NAEH) on dilation and curettage (D&C). We will be able to estimate the risk of a postmenopausal female patient with uterine bleeding during an OAT to have a precancerous endometrial lesion. : The subjects of the study were 173 female patients with uterine bleeding, who have had total hysterectomy with bilateral salpingoovarectomy, of whom 99 underwent an OAT. There were 101 female patients initially diagnosed with NAEH, of which 60 did not have anticoagulant treatment (mean age 57.36 ± 6.51) and 41 had anticoagulant treatment (mean age 60.39 ± 7.35) ( = 0.006). From the pathology diagnosis moment, the surgery was performed at 42.09 ± 14.54 days in patients without OAT and after 35.39 ± 11.29 days in those who received such treatment ( = 0.724). : Initial diagnosis of NAEH established at D&C was changed at the final diagnosis after hysterectomy in EH with cellular atypia (atypical endometrial hyperplasia AEH) or EC in 18.18% of patients without OAT, and in 40.54% of patients who received this treatment. : Based on a logistic regression model, it is estimated that female patients with an initial histopathological diagnosis of NAEH and who underwent OAT have, on average, 4.85 times greater odds (OR = 4.85, 95% CI 1.79-14.06) than the others of being identified postoperatively with more advanced lesions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539967PMC
http://dx.doi.org/10.3390/medicina57101003DOI Listing

Publication Analysis

Top Keywords

endometrial hyperplasia
20
uterine bleeding
16
initial diagnosis
12
anticoagulant treatment
12
female patients
12
patients
10
advanced lesions
8
endometrial
8
non-atypical endometrial
8
oral anticoagulant
8

Similar Publications

In dogs, the characterization of intraluminal uterine contents has been subjectively carried out by the operators. The aims of this study were: 1) To ultrasonographically describe and compare the echogenicity and heterogeneity of the intraluminal uterine contents in bitches using digital analysis; 2) To assess the cytology of the uterine contents; 3) To evaluate the effect of clinical, ultrasonographic, bacteriological and cytological parameters on intraluminal contents echogenicity and heterogeneity. Twenty-one intact, 3-24 kg, 1-12 years of age, female dogs with ultrasonographically detected uterine content were included.

View Article and Find Full Text PDF

Introduction: This study evaluated the safety and tolerability of fezolinetant in women with vasomotor symptoms (VMS) due to menopause in a pooled analysis of data from three 52-week phase 3 studies (SKYLIGHT 1, 2, and 4).

Methods: SKYLIGHT 1 and 2 were double-blind, placebo-controlled studies where women (≥ 40 to ≤ 65 years), with moderate to severe VMS (minimum average ≥ 7 hot flashes/day) were randomized to once-daily placebo, fezolinetant 30 mg or 45 mg. After 12 weeks, those on placebo were re-randomized to fezolinetant 30 mg or 45 mg, while those on fezolinetant continued on their assigned dose for 40 weeks.

View Article and Find Full Text PDF

PATHOMORPHOLOGICAL AND CLINICAL CHARACTERISTICS OF THE UTERUS IN COMBINED ADENOMYOSIS AND MYOMA.

Georgian Med News

October 2024

Azerbaijan Medical University, Department of Obstetrics and Gynecology II, Baku, Azerbaijan.

The Aim Of The Study: to examine the pathomorphological and clinical characteristics of the uterus in the combined form of fibroids and adenomyosis.

Methods: The research work was conducted within the framework of the scientific program of the Department of Obstetrics and Gynecology II at Azerbaijan Medical University for the years 2021-2024. In the course of this study, a comprehensive clinical, laboratory, and instrumental prospective examination was conducted on 113 patients aged 30 to 50 years (mean age 42,0±1,8 years) with combined adenomyosis and uterine fibroids.

View Article and Find Full Text PDF

Introduction: Appendiceal endometriosis (AE) is a rare condition, with a prevalence ranging from 0.05 % to 1.7 % in patients with endometriosis.

View Article and Find Full Text PDF

Objective: Aim: Investigation of hyperproliferative diseases of the female genital organs as a consequence of mixed urogenital infections.

Patients And Methods: Materials and Methods: The study included 56 women of reproductive age who experienced discomfort in the external genital area in the form of excessive vaginal discharge and/or unpleasant odour of the discharge, itching in the external genital area (main group). The control group consisted of 30 somatically and gynaecologically healthy patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!